Literature DB >> 17458656

Postoperative pulmonary thromboembolism possibly associated with recombinant activated factor VII infusion for the treatment of uncontrolled hemorrhage during vertebral instrumentation.

Zahid Hussain Khan1, Alireza Ebrahim Soltani, Payman Rahmani.   

Abstract

We report the successful use of recombinant activated factor VII (rFVIIa) infusion in an 18-year-old man who underwent L3 laminectomy and pedicular screw fixation with severe refractory bleeding secondary to severe coagulopathy, which had remained unresponsive to conventional medical and surgical therapies. However, the patient developed a thromboembolic complication presumably associated with the use of rFVIIa. Although rFVIIa provides a dramatic response in intractable bleeding, it may cause a thromboembolic phenomenon which should be vigilantly considered and promptly treated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17458656     DOI: 10.1007/s00540-006-0481-y

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  17 in total

1.  Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint.

Authors:  B R Saxon; D Shanks; C B Jory; V Williams
Journal:  Thromb Haemost       Date:  2001-10       Impact factor: 5.249

2.  Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura.

Authors:  Srdana Culić
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

3.  Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.

Authors:  Kenneth David Boffard; Bruno Riou; Brian Warren; Philip Iau Tsau Choong; Sandro Rizoli; Rolf Rossaint; Mads Axelsen; Yoram Kluger
Journal:  J Trauma       Date:  2005-07

4.  Effect of recombinant factor VIIa (Novoseven) on thrombocytopenia-like conditions in vitro.

Authors:  M Kjalke; M Johannessen; U Hedner
Journal:  Semin Hematol       Date:  2001-10       Impact factor: 3.851

5.  Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate.

Authors:  Ruby Anne E Deveras; Craig M Kessler
Journal:  Ann Intern Med       Date:  2002-12-03       Impact factor: 25.391

Review 6.  Inhibitor antibodies to factor VIII and factor IX: management.

Authors:  J M Lusher
Journal:  Semin Thromb Hemost       Date:  2000       Impact factor: 4.180

7.  Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment.

Authors:  C Barnes; V Blanchette; P Canning; M Carcao
Journal:  Transfus Med       Date:  2005-04       Impact factor: 2.019

8.  Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.

Authors:  Grigoris T Gerotziafas; Costas Zervas; George Gavrielidis; Aggelos Tokmaktsis; Evdoxia Hatjiharissi; Mary Papaioannou; Anna Lazaridou; Nikos Constantinou; Meyer Michel Samama; John Christakis
Journal:  Am J Hematol       Date:  2002-03       Impact factor: 10.047

9.  Clinical experience with recombinant factor VIIa.

Authors:  J Lusher; J Ingerslev; H Roberts; U Hedner
Journal:  Blood Coagul Fibrinolysis       Date:  1998-03       Impact factor: 1.276

Review 10.  Recombinant activated factor VII as a universal haemostatic agent.

Authors:  U Hedner
Journal:  Blood Coagul Fibrinolysis       Date:  1998-03       Impact factor: 1.276

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.